New Enterprise Associates Discloses 22.2% Stake in SpyGlass Pharma Post-IPO
Summary
New Enterprise Associates (NEA) and its affiliates reported a substantial 22.2% beneficial ownership in SpyGlass Pharma, Inc. following the company's recent IPO and conversion of preferred stock.
Key Events
-
Significant Institutional Ownership
New Enterprise Associates (NEA) and its affiliates reported a 22.2% beneficial ownership in SpyGlass Pharma, Inc.
-
Post-IPO Stake
The ownership includes shares acquired through the conversion of preferred stock and a $15 million purchase at the IPO price of $16.00 per share.
-
Investor Rights and Lock-up
NEA holds demand and piggyback registration rights and is subject to a 180-day lock-up agreement following the IPO.
Analysis
This Schedule 13D filing reveals that New Enterprise Associates (NEA), a prominent venture capital firm, along with its affiliated funds and managers, holds a significant 22.2% stake in SpyGlass Pharma, Inc. The ownership primarily stems from the conversion of various series of preferred stock into common stock and an additional $15 million purchase at the IPO price of $16.00 per share. This substantial post-IPO ownership by a major institutional investor signals strong confidence in the company's long-term prospects, especially as the stock trades near its 52-week high. The filing also details standard investor rights, including demand and piggyback registration rights, and confirms a 180-day lock-up period for NEA's shares, indicating a commitment to holding the position for the near term.
At the time of this filing, SGP was trading at $28.22 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $940.2M. The 52-week trading range was $24.71 to $29.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.